December 12, 2018

Apellis Pharmaceuticals case study

This diagram illustrates the central role of C3 in the complement cascade, a key part of the immune system. It shows how the Alternative Pathway, Lectin Pathway, and Classical Pathway all converge on C3, leading to downstream effects like membrane attack, phagocytosis, and inflammation. This highlights the target of Apellis's therapeutic development.

When Apellis Pharmaceuticals, the clinical-stage biopharmaceutical company, was faced with delivering a complex story to 100 potential investors, Steve Axon – Chief Business Officer – knew they needed help. “We had […]